Martin S. Hirsch, M.D.
Professor of Medicine
Harvard Medical School
Professor in the Department of Immunology & Infectious Diseases
Harvard School of Public Health
Director, Clinical AIDS Research
Infectious Disease Unit
Department of Medicine
Massachusetts General Hospital
Fruit Street, Boston, MA 02114
Tel: (617) 726-3812
Fax: (617) 726-7416
e-mail: hirsch.martin@mgh.harvard.edu
Our laboratory studies the pathogenesis and therapy of infections with both HIV and human herpes viruses, including cytomegalovirus (CMV) and HHV8. Therapeutic studies evaluate new strategies for the control of both HIV and CMV, in vitro and in patients. Promising combination regimens are employed, and resistance to antivirals is investigated.
Current efforts are directed toward:
- Evaluating combination strategies against HIV isolates resistant to current antiretrovirals.
- Comparing strategies of early intensive therapy versus induction-consolidation regimens.
- Ex vitro expansion of CD4+ lymphocytes from infected individuals in the presence of combination antiretrovirals for eventual gene therapy/lymphocyte infusion trials.
Selected Publications
Wilson CC, Wong JT, Girard DD, Merrill DP, Dyan M, An DD, Kalams SA, Johnson RP, Hirsch MS, D'Aquila RT, and Walker BD. Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents. J Infect Dis 1995;172:88-96.
Mazzuli T, Rusconi S, Merrill DP, D'Aquila RT, Moonis M, Chou TC, and Hirsch MS. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Ag Chemother 1994;38:656-61.
Rusconi S, Merrill DP, and Hirsch MS. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J Infect Dis 1994;170:1361-66.
Johnson VA, Merrill DP, Chou TC, and Hirsch MS. HIV-1 inhibitory interactions between protease inhibitor (RO31-8959) and either zidovudine (AZT), 2'3'-dideoxycytidine (ddC), or recombinant interferon-alpha A (rIFNa) against AZT-sensitive or AZT-resistant HIV-1 in vitro. J Infect Dis 1992;166:1143-46.
Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, D'Aquila RT, and Hirsch MS. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant HIV-1 synergistically in vitro. J Infect Dis 1991;164:656-65. |
